← Leaderboards
Brian F Volkman
University Of Wisconsin Madison
$22,998,631
Attributed
$26,282,399
Total exposure
22
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,282,399 · 22
By mechanism
R01$14,012,212 · 7
R44$3,650,686 · 2
S10$3,100,000 · 3
R37$2,371,133 · 1
R56$1,476,921 · 4
U54$1,175,471 · 1
Top collaborators
- Michael B Dwinell3 shared
- William R Clarke2 shared
- Mitchell H Grayson2 shared
- Chad Allen Koplinski2 shared
- Anthony E Getschman1 shared
Others in their field
Top investigators on “Chemokine”
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- Andrew D Luster · Massachusetts General Hospital$27,938,802
- Joan Weinberger Berman · Yeshiva University$24,229,643
- Larry Arthur$22,516,306
- Maurizio Fava · Massachusetts General Hospital$19,116,294
- Lionel B Ivashkiv · Hospital For Special Surgery$18,420,856
Research focus
ChemokineProteinsG-Protein-Coupled ReceptorsStructureReceptorInflammationFamilyLigandsSignal TransductionChemokine ReceptorDesignTissuesBaseCellsIn VivoMalignant NeoplasmsSiteMigrationSmall MoleculeBiologicalMolecularTyrosine O-SulfateN-TerminalCell Motility
Grant awards (69)
Structure-based inhibition of chemokine signaling in the inflamed pancreas$643,818
R01 · FY2025 · DK · contact PI
Evolution and design of metamorphic fold-switching proteins$554,302
R01 · FY2025 · AI · contact PI
Structural Basis for Chemokine Function$446,133
R37 · FY2025 · AI · contact PI
Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation$966,201
R44 · FY2024 · AR
Structure-based inhibition of chemokine signaling in the inflamed pancreas$617,998
R01 · FY2024 · DK · contact PI
Evolution and design of metamorphic fold-switching proteins$554,302
R01 · FY2024 · AI · contact PI
Structural Basis for Chemokine Function$385,000
R37 · FY2024 · AI · contact PI
Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation$998,606
R44 · FY2023 · AR
Structure-based inhibition of chemokine signaling in the inflamed pancreas$662,744
R01 · FY2023 · DK · contact PI
Evolution and design of metamorphic fold-switching proteins$626,404
R01 · FY2023 · AI · contact PI
Structural Basis for Chemokine Function$385,000
R37 · FY2023 · AI · contact PI
Structural Basis for Chemokine Function$385,000
R37 · FY2022 · AI · contact PI
Development of an engineered CCL20 protein as a lead therapeutic molecule for psoriasis$829,097
R44 · FY2021 · AR · contact PI
Evolution of fold-switching in the metamorphic chemokine XCL1$390,000
R56 · FY2021 · AI · contact PI
Structural Basis for Chemokine Function$385,000
R37 · FY2021 · AI · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$305,720
R01 · FY2021 · GM · contact PI
Development of an engineered CCL20 protein as a lead therapeutic molecule for psoriasis$856,782
R44 · FY2020 · AR
Structural Basis for Chemokine Function$385,000
R37 · FY2020 · AI · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$305,720
R01 · FY2020 · GM · contact PI
800 MHz NMR Spectrometer for Southeast Wisconsin$2,000,000
S10 · FY2019 · OD · contact PI
Structural Basis for Chemokine Function$344,250
R01 · FY2019 · AI · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$305,720
R01 · FY2019 · GM · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$200,000
R01 · FY2019 · GM · contact PI
Targeting CCL28 as therapy for obstructive lung disease$385,000
R01 · FY2018 · AI · contact PI
Structural Basis for Chemokine Function$344,250
R01 · FY2018 · AI · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$319,220
R01 · FY2018 · GM · contact PI
Development of an engineered CCL20 protein as a lead therapeutic molecule for Psoriasis$224,999
R43 · FY2018 · AR
Targeting CCL28 as therapy for obstructive lung disease$385,000
R01 · FY2017 · AI · contact PI
Structural Basis for Chemokine Function$344,250
R01 · FY2017 · AI · contact PI
Targeting CCL28 as therapy for obstructive lung disease$385,000
R01 · FY2016 · AI · contact PI
Structural Basis for Chemokine Function$344,250
R01 · FY2016 · AI · contact PI
High Performance Digital Console and Sample Jet$600,000
S10 · FY2015 · OD · contact PI
Targeting CCL28 as therapy for obstructive lung disease$384,791
R01 · FY2015 · AI · contact PI
Structural Basis for Chemokine Function$344,250
R01 · FY2015 · AI · contact PI
Targeting CCL28 as therapy for obstructive lung disease$382,500
R56 · FY2014 · AI · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$282,925
R01 · FY2014 · GM · contact PI
Structural and energetic origins of metamorphic protein folding$352,675
R56 · FY2013 · AI · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$314,012
R01 · FY2013 · GM · contact PI
Structural Basis for Chemokine Function$277,933
R01 · FY2013 · AI · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$410,351
R01 · FY2012 · GM · contact PI
Structural Basis for Chemokine Function$295,674
R01 · FY2012 · AI · contact PI
Conformational duality in the human chemokine Ltn/XCL1$351,746
R56 · FY2011 · AI · contact PI
Structural Basis for Chemokine Function$299,549
R01 · FY2011 · AI · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$296,175
R01 · FY2011 · GM · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$84,950
R01 · FY2011 · GM · contact PI
Sulfotyrosine-guided discovery of small molecule chemokine inhibitors$76,020
R01 · FY2011 · GM · contact PI
Structural basis for selctive lysis of anthrax and drug-resistant S. aureus$602,825
U54 · FY2010 · AI · contact PI
Structural Basis for Chemokine Function$361,236
R01 · FY2010 · AI · contact PI
Structural basis for selctive lysis of anthrax and drug-resistant S. aureus$572,646
U54 · FY2009 · AI · contact PI
500 MHz NMR Spectrometer at the Medical College of Wisconsin$500,000
S10 · FY2009 · RR · contact PI
Conformational duality in the human chemokine Ltn/XCL1$264,116
R01 · FY2009 · AI · contact PI
Conformational duality in the human chemokine Ltn/XCL1$45,265
R01 · FY2009 · AI · contact PI
Conformational duality in the human chemokine Ltn/XCL1$264,116
R01 · FY2008 · AI · contact PI
Structural Basis for Chemokine Function$246,610
R01 · FY2008 · AI · contact PI
Conformational duality in the human chemokine Ltn/XCL1$269,231
R01 · FY2007 · AI · contact PI
Structural Basis for Chemokine Function$251,387
R01 · FY2007 · AI · contact PI
Conformational duality in the human chemokine Ltn/XCL1$277,273
R01 · FY2006 · AI · contact PI
Structural Basis for Chemokine Function$258,895
R01 · FY2006 · AI · contact PI
Conformational duality in the human chemokine Ltn/XCL1$296,820
R01 · FY2005 · AI
Structural Basis for Chemokine Function$265,125
R01 · FY2005 · AI
T-CELL AND NEUTROPHIL ISOLATION FROM FRESH WHOLE BLOOD$3,944
M01 · FY2005 · RR
Structural Basis for Chemokine Function$132,563
R01 · FY2004 · AI
Structure of the Human Chemokine Lymphotactin$259,500
R21 · FY2003 · AI
PULSE SEQUENCE DEVELOPMENT$0
P41 · FY2002 · RR
STRUCTURE OF THE HUMAN CHEMOKINE LYMPHOTACTIN$198,950
R01 · FY2001 · AI
PULSE SEQUENCE DEVELOPMENT$0
P41 · FY2001 · RR
STRUCTURE OF THE HUMAN CHEMOKINE LYMPHOTACTIN$159,840
R01 · FY2000 · AI
STRUCTURE OF THE HUMAN CHEMOKINE LYMPHOTACTIN$26,207
R01 · FY2000 · AI
PULSE SEQUENCE DEVELOPMENT$7,533
P41 · FY2000 · RR